재조합 DNA 기술 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 구성요소별, 용도별, 최종 용도별, 부문별 예측(2024-2030년)

Recombinant DNA Technology Market Growth & Trends:

The global recombinant DNA technology market size is expected to reach USD 1,067.1 billion by 2030, expanding at a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary product development, genetically modified crop development, biopesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.

The use of Genetically Modified (GM) products, such as GM animals, developed using the rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess GM product safety in context to its impact on human health and the environment.

In addition, there is a rising need to improve the recombinant proteins' production capacity by several folds, owing to an increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.

As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected to bolster the adoption of rDNA technology for non-traditional applications.

Recombinant DNA Technology Market Report Highlights:

• Medical rDNA products dominated the share in 2023 in terms of revenue generation.
• This can be attributed to the commercial success of insulin which has prompted firms for further development of recombinant drugs.
• Owing to efficient transient and stable expression capabilities, mammalian expression system captured the largest share.
• This share is also supported by the improvements in media for high yield using a mammalian expression system.
• Health & disease accounted with the largest share in terms of revenue.
• Gene therapy, antibodies production, drug metabolism investigation, recombinant therapeutic & vaccine development are recognized as major applications of this technology in human healthcare management.
• Various end-use segments served by this recombinant DNA technology market encompass pharmaceutical & biotech entities, academic & research institutes, and other industrial entities.
• End-use wise, pharmaceutical and biotechnology firms are estimated to be the largest segment owing to the presence of a substantial number of biopharma entities that have adopted rDNA products.
• North America held the largest share owing to the presence of effective regulations pertaining to the approval of recombinant therapeutics as well as GM products.
• Asia Pacific is expected to emerge as the fastest growing regional market.
• Conducting clinical trials in Asian countries such as India is relatively less expensive compared to western countries. This has resulted in the migration of several global biopharmaceutical developers towards this region.
• Biogen; Amgen Inc., Eli Lilly and Company, Monsanto Company, Novartis AG, and F. Hoffmann-La Roche Ltd are some of the major companies operating in this space.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Recombinant DNA Technology Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Recombinant DNA Technology Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Recombinant DNA Technology Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Recombinant DNA Technology Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
• 4.3. Medical
  • 4.3.1. Medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.3.2. Therapeutic Agent
    • 4.3.2.1. Therapeutic Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.3.3. Human Protein
    • 4.3.3.1. Human Protein Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.3.4. Vaccine
    • 4.3.4.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. Non-medical
  • 4.4.1. Non-medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4.2. Biotech Crops
    • 4.4.2.1. Biotech Crops Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4.3. Specialty Chemicals
    • 4.4.3.1. Specialty Chemicals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4.4. Other Non-medical Products
    • 4.4.4.1. Other Non-medical Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Recombinant DNA Technology Market: Component Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Recombinant DNA Technology Market: Component Movement Analysis, 2023 & 2030 (USD Billion)
• 5.3. Expression System
  • 5.3.1. Expression System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3.2. Mammalian
    • 5.3.2.1. Mammalian Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3.3. Bacteria
    • 5.3.3.1. Bacteria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3.4. Yeast
    • 5.3.4.1. Yeast Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3.5. Baculovirus / Insect
    • 5.3.5.1. Baculovirus / Insect Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3.6. Other Expression Systems
    • 5.3.6.1. Other Expression Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Cloning Vector
  • 5.4.1. Cloning Vector Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Recombinant DNA Technology Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Recombinant DNA Technology Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
• 6.3. Food & Agriculture
  • 6.3.1. Food & Agriculture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Health & Disease
  • 6.4.1. Health & Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4.2. Human
    • 6.4.2.1. Human Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4.3. Animal
    • 6.4.3.1. Animal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Other Applications
  • 6.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Recombinant DNA Technology Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Recombinant DNA Technology Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
• 7.3. Biotechnology and Pharmaceutical Companies
  • 7.3.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Academic & Government Research Institutes
  • 7.4.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Other End Uses
  • 7.5.1. Other End Uses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Recombinant DNA Technology Market: Regional Estimates & Trend Analysis

• 8.1. Recombinant DNA Technology Market Share, By Region, 2023 & 2030 (USD Billion)
• 8.2. North America
  • 8.2.1. North America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.3. Europe
  • 8.3.1. Europe Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.2. UK
    • 8.3.2.1. UK Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.4. France
    • 8.3.4.1. France Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.5. Italy
    • 8.3.5.1. Italy Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.6. Spain
    • 8.3.6.1. Spain Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3.9. Norway
    • 8.3.9.1. Norway Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.3. China
    • 8.4.3.1. China Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.4. India
    • 8.4.4.1. India Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.6. Australia
    • 8.4.6.1. Australia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.7. Thailand
    • 8.4.7.1. Thailand Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.5. Latin America
  • 8.5.1. Latin America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. UAE Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Pfizer Inc.
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/Strategic Initiatives
  • 9.4.2. Sanofi
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/Strategic Initiatives
  • 9.4.3. New England Biolabs
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/Strategic Initiatives
  • 9.4.4. GlaxoSmithKline plc
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/Strategic Initiatives
  • 9.4.5. GenScript
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/Strategic Initiatives
  • 9.4.6. Thermo Fisher Scientific Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/Strategic Initiatives
  • 9.4.7. Biogen Inc.
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/Strategic Initiatives
  • 9.4.8. Merck & Co., Inc.
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/Strategic Initiatives
  • 9.4.9. Amgen Inc.
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/Strategic Initiatives
  • 9.4.10. Monsanto Company
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/Strategic Initiatives
  • 9.4.11. F. Hoffmann-La Roche Ltd
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments/Strategic Initiatives
  • 9.4.12. Novartis AG
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments/Strategic Initiatives
  • 9.4.13. Eli Lilly and Company
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments/Strategic Initiatives